New study tracks PRRT effects on neuroendocrine tumors

NCT ID NCT04090034

First seen Mar 22, 2026 · Last updated Apr 29, 2026 · Updated 7 times

Summary

This study is gathering information on how well peptide receptor radionuclide therapy (PRRT) works for people with neuroendocrine tumors that started in the stomach, intestines, or pancreas. Researchers will track patient details, tumor changes, survival, and side effects. The goal is to better understand who benefits most from this treatment and what to expect.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Research Institute at Methodist Health System

    RECRUITING

    Dallas, Texas, 75203, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Methodist Dallas Medical Center

    ENROLLING_BY_INVITATION

    Dallas, Texas, 75203, United States

Conditions

Explore the condition pages connected to this study.